To study the therapeutic efficacy of the systemically bioavailable ASBT inhibitor AS0369, we used an animal model of obstructive cholestasis where four distinct stages ranging from an early to a severe stage of CN can be reproducibly generated. This evidence concerns the gene SLC10A2 and cyclic hematopoiesis.